Education
About Us
Working with TipRanks
Follow Us
LifeMD (LFMD)
NASDAQ:LFMD
Earnings Data
Report Date
May 09, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.19Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 10, 2025
|% Change Since: 40.52%
|Next Earnings Date:May 09, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in telehealth revenue and successful product launches, contributing to optimistic financial guidance for 2025. However, challenges such as declining gross margins and uncertainties in the compounded GLP-1 medication market were noted.Company Guidance
In the recent earnings call, LifeMD, Inc. provided an optimistic outlook for 2025 following a strong performance in 2024. The company's revenue guidance for 2025 is set at $265 million to $275 million, with telehealth revenue projected between $205 million and $213 million, marking significant growth from 2024's consolidated revenue of $212.5 million. The telehealth segment is expected to see adjusted EBITDA grow to approximately $20 million. The company highlighted a robust increase in telehealth revenue, which grew 60% for the quarter, and an impressive fivefold rise in telehealth adjusted EBITDA. LifeMD also emphasized the expansion of its insurance coverage, aiming to have approximately 150 million lives under coverage by the end of 2025. Additionally, the company is focusing on strategic initiatives, such as the launch of a hormone replacement therapy on the Rex MD platform and the introduction of LifeMD plus membership, which is expected to enhance patient experience and improve compliance. The company's continued investment in insurance infrastructure and pharmacy capabilities is anticipated to drive long-term growth and profitability.Significant Telehealth Revenue Growth
Telehealth revenue grew by 60% year-over-year for the fourth quarter, with standalone adjusted EBITDA growing nearly fivefold.
Successful Product Launches
Key product launches included male hormone replacement therapy, a nationwide pharmacy licensed in 47 states, and expanded medical infrastructure.
Strong Performance in Rex MD
Rex MD produces over $80 million in annualized revenue, with expected growth of 15% to 20% in 2025.
Expansion of Medicare Offerings
LifeMD plans to launch fee-for-service Medicare offerings, targeting 24.5 million Medicare beneficiaries.
Increased Insurance Coverage for GLP-1 Medications
18 percentage point increase in approval rate for Zepbound, with prior authorization approval rates approaching 60%.
Strong Financial Guidance for 2025
Guidance for 2025 consolidated revenue of $265 million to $275 million, with telehealth revenue of $205 million to $213 million.
---
LFMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LFMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 10, 2025 | $4.27 | $5.58 | +30.68% |
| Nov 07, 2024 | $5.13 | $5.85 | +14.04% |
| Aug 07, 2024 | $5.37 | $5.22 | -2.79% |
| May 08, 2024 | $12.33 | $9.30 | -24.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does LifeMD (LFMD) report earnings?
LifeMD (LFMD) is schdueled to report earning on May 09, 2025, TBA Not Confirmed.
What is LifeMD (LFMD) earnings time?
LifeMD (LFMD) earnings time is at May 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LFMD EPS forecast?
LFMD EPS forecast for the fiscal quarter 2025 (Q1) is -0.05.
---